CClinicalTrials.gg
RecruitingNCT05873634Updated Sep 29, 2026

HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets

An observational study in Heart Failure and Heart Failure With Preserved Ejection Fraction, sponsored by Northwestern University. Recruiting at 6 sites in United States. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Northwestern University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
30 Years and older
Sex
All
01

Study summary

HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.

02

Conditions studied

  • Heart Failure
  • Heart Failure With Preserved Ejection Fraction

Browse trials for

03

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults over 30 years of age.

Inclusion criteria

HF Inclusion Criteria (HeartShare Registry)

  1. Age ≥30 years.
  2. Prior diagnosis of HF in the EHR (any left ventricular ejection fraction).

Non-HF Group Inclusion Criteria (HeartShare Registry)

  1. Age ≥30 years.
  2. No known prior diagnosis of HF or use of loop diuretics.
  3. No known prior history of BNP >100 pg/ml or NTproBNP >300 pg/ml, if prior laboratory tests are available in the EHR.

HFpEF Inclusion Criteria (HeartShare Deep Phenotyping Cohort)

  1. Age ≥30 years.
  2. Left ventricular ejection fraction ≥50% measured by echocardiography.
  3. Definition of HFpEF: signs and symptoms of HF, NYHA functional class II-IV, and at least one of the following:

    1. Elevated BNP (≥75 pg/ml in sinus rhythm or ≥225 pg/ml in atrial fibrillation/flutter) or NTproBNP (≥225 pg/ml in sinus rhythm or ≥675 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center.
    2. Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels [using the thresholds listed above], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography).
    3. Elevated pulmonary capillary wedge pressure (PCWP) at rest (≥15 mmHg) or during exercise (≥25 mmHg for supine exercise or PCWP/cardiac output ratio ≥2 mmHg/L/min for upright exercise).
    4. Elevated H2FPEF score26 (≥5) or HFA-PEFF27 score (≥5).

Non-HFpEF Group Inclusion Criteria (HeartShare Deep Phenotyping Cohort)

  1. Age ≥30 years.
  2. Left ventricular ejection fraction ≥50% measured by echocardiography.
  3. No known prior diagnosis of HF or use of diuretics for fluid management.
  4. No known prior history of BNP ≥75 pg/ml or NTproBNP ≥225 pg/ml, if prior laboratory tests are available in the EHR.
  5. BNP \<75 pg/ml or NTproBNP \<225 pg/ml at the time of screening. Choice of BNP or NTproBNP is based on availability at each clinical center.

Exclusion criteria

Exclusion Criteria:

Exclusion Criteria (HeartShare Registry) The following exclusion criteria apply to both HF and non-HF group participants, unless otherwise indicated.

  1. For non-HF group: any prior known left ventricular ejection fraction \<50%.
  2. Prior history of solid organ transplantation.
  3. Prior history of mechanical circulatory support.
  4. Prior history of non-cardiac cirrhosis.
  5. Inability to provide written consent to the study.

Exclusion Criteria (HeartShare Deep Phenotyping Cohort) The following exclusion criteria apply to both HFpEF and non-HFpEF group participants, unless otherwise indicated.

  1. Life expectancy estimated to be \< 1 year.
  2. Primary cardiomyopathy (including amyloid, hypertrophic cardiomyopathy, cardiac sarcoidosis, hemochromatosis, or other infiltrative cardiomyopathies) or pulmonary arterial hypertension (WHO Group I, III, or IV pulmonary hypertension).
  3. Any prior known left ventricular ejection fraction \<40%, except if this occurred only in the setting of an acute tachycardia episode (e.g., acute atrial fibrillation).
  4. Clinically significant valvular heart disease defined as:

    1. Moderate to greater aortic stenosis, pulmonic stenosis, or tricuspid stenosis.
    2. Any mitral stenosis.
    3. Moderate or greater aortic regurgitation.
    4. Greater than moderate mitral regurgitation.
  5. Any planned cardiac surgery or cardiac intervention in the next 3 months.
  6. Alternative primary reason for symptoms of shortness of breath and exercise intolerance in HFpEF participants in the opinion of the enrolling investigator.
  7. Cardiac surgery, acute coronary syndrome, percutaneous coronary intervention, stroke, transient ischemic attack, or carotid intervention in the preceding 6 months prior to enrollment.
  8. Known symptomatic epicardial coronary artery disease that is not revascularized.
  9. Any non-elective hospitalization in the preceding 2 weeks.
  10. Prior history of solid organ transplantation.
  11. Prior history of chronic infection (HIV, hepatitis C, hepatitis B, tuberculosis) unless treated and not clinically active in the opinion of the enrolling investigator.
  12. Prior history of mechanical circulatory support.
  13. Prior history of non-cardiac cirrhosis.
  14. Estimated GFR \<20 ml/min/1.73m2 or currently on dialysis.
  15. Any condition that may preclude participation or adherence to the study protocol, in the opinion of the enrolling investigator.
  16. Inability to provide written consent to the study.
  17. Current acute decompensated heart failure.
  18. Currently pregnant.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
4 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • HFpEF

    Participants with HFpEF

  • Non-HFpEF

    Participants without HFpEF

05

What researchers measure

Primary outcomes

  1. Number of participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

    Time frame: Up to 5 years

06

Study locations

4 of 6 sites recruiting
  • University of California Davis
    Sacramento, California 95817, United States
    • Maiya Her · Contact · 916-734-0230
    • Nipavan Chiamvimonvat, MD · Principal investigator
    • Javier Lopez, MD · Sub investigator
    • Martin Cadeiras, MD · Sub investigator
    Recruiting
  • Northwestern University
    Chicago, Illinois 60611, United States
    • Laura Alagna · Contact · laura.alagna@northwesterne.du · 312-695-6765
    • Sadiya Khan, MD · Principal investigator
    • Laura Rasmussen-Torvik, PhD, MPH · Principal investigator
    Recruiting
  • Mass General Brigham
    Boston, Massachusetts 02114, United States
    • Diane Cocca-Spofford · Contact · dcoccaspofford@mgh.harvard.edu · 617-726-8228
    • Greg Lewis, MD · Principal investigator
    • Akshay Desai, MD, MPH · Sub investigator
    • Michael Givertz, MD · Sub investigator
    • Scott Solomon, MD · Sub investigator
    Not yet recruiting
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    • Matthew Adolphsen · Contact · Adolphsen.Matthew@mayo.edu · 507-422-5919
    • Barry Borlaug, MD · Principal investigator
    • Margaret Redfield, MD · Sub investigator
    Recruiting
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
    • Ben Nelson · Contact · 336-716-6789
    • Dalane Kitzman, MD · Principal investigator
    • Alain Bertoni, MD, MPH · Sub investigator
    Not yet recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    • Tiffany Sharkoski · Contact · 215-615-2354
    • Julio Chirinos, MD, PhD · Principal investigator
    Recruiting
07

Registry details

Key details

Study ID
NCT05873634
Lead sponsor
Northwestern University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Massachusetts General Hospital, Brigham and Women's Hospital, Mayo Clinic, University of California, Davis, Wake Forest University Health Sciences, University of Pennsylvania
Responsible party
Sanjiv Shah (Stone Endowed Professor of Medicine, Director of Research, Bluhm Cardiovascular Institute, Principal Investigator, HeartShare Data Translation Center, Northwestern University) — Principal investigator
First posted
May 24, 2023
Start date
Mar 1, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Laura Alagna
Contact
heartsharestudy@northwestern.edui
312-695-6765
Sanjiv Shah, MD
principal investigator · Northwestern University
Svati Shah, MD, MHS
study chair · Duke University
Javed Butler, MPH, MBA
study chair · Baylor Scott and White Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion